1-[6-Ethyl-8-Fluoro-4-Methyl-3-(3-Methyl-1,2,4-Oxadiazol-5-Yl)Quinolin-2-Yl]-N-(Oxan-4-Yl)Piperidin-4-Amine

2 trials NNeurology/Psychiatry

Filter these 2 trials by condition, phase, country and more.

Open in Search →

2 Registered trials

0 Recruiting

2 Completed trials

1 Sponsors

7 Countries

Phase III

Phase III: 2

Sponsors using this IMP

Neumora Therapeutics Inc. 2

All trials

2 total

Long-term Study to Assess the Safety and Effectiveness of NMRA-335140 in Participants with Major Depressive Disorder Ended

2023-505892-56-00 Phase III 7 countries Neumora Therapeutics Inc.
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-335140 versus Placebo in Participants wit… Ended

2023-506335-15-00 Phase III 7 countries Neumora Therapeutics Inc.

Showing 1–2 of 2 trials

← All drugs A–Z